Results 171 to 180 of about 231,349 (305)

β‐Adrenergic Signaling Promotes Anti‐Tumor Immunity in TP53‐mutant Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
β‐adrenergic stimulation enhances anti‐tumor immunity in TP53‐deficient oral squamous cell carcinoma by inducing tumor‐derived secretion of CXCL10, which attracts and activates cytotoxic CD8+ T cells. The findings demonstrate that β‐adrenergic signaling alters tumor–immune interactions via CXCL10‐mediated paracrine activation, revealing a neuro‐immune ...
Frederico O. Gleber‐Netto, Deborah Silverman, Tongxin Xie, Shamima Akhter, Nicole R. Vaughn, Adewale Adebayo, Kala Chand Debnath, Shorook Naara, Shajedul Islam, Erik Knutsen, Emily Lorin Ashkin, Simone Anfossi, Sara Leahey, Patrick Hwu, Sebastien Talbot, Erica K Sloan, Robert Saddawi‐Konefka, Roberto Rangel, Jeffrey N. Myers, George A. Calin, Moran Amit   +20 more
wiley   +1 more source

PET Imaging of Cardiac Inflammation in Viral Myocarditis Using a DPP4‐Targeted Probe

Advanced Science, EarlyView.
This study describes a DPP4‐targeted PET probe for imaging myocardial inflammation by selectively targeting activated immune cells. Derived from the clinically approved small‐molecule inhibitor linagliptin, the probe demonstrates favorable biodistribution with specific cardiac uptake in myocarditis.
Wanhao Gao, Wenzhu Hu, Du Tang, Xinxin Liu, Kun Yu, Lixia Feng, Minyu Liao, Wang Lin, Wenqiang Zhu, Sanjay Rajagopalan, Xiaoli Lan, Jixin Zhong, Dao Wen Wang, Dawei Jiang, Xiaoquan Rao   +14 more
wiley   +1 more source

Advances in Immune Checkpoint Inhibitors for Cancer Treatment. [PDF]

Cancers (Basel)
Chen K, Zhu F, Li X, Yoshimura T.
europepmc   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, EarlyView.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Immune checkpoint inhibitors for invasive mucinous adenocarcinoma: A case series. [PDF]

Oncol Lett
Kato T, Mitsumura T, Tsuboi E, Nakahama H, Takahashi Y, Nei Y, Hanada S, Miyamoto A, Uruga H, Fujii T, Tamaoka M.   +10 more
europepmc   +1 more source

Self‐Assembling Hybrid Hydrogel Reprograms the Stromal Vascular Fraction to Treat Osteoarthritis

Advanced Science, EarlyView.
This study presents a bioinspired injectable hydrogel that enhances the therapeutic potential of stem cell‐rich stromal vascular fraction for treating osteoarthritis. By reprogramming cell behavior through epigenetic modulation, the hydrogel promotes cartilage regeneration and reduces joint damage in a rat model, offering a promising new approach for ...
Waifang Hou, Yongfeng Chen, Longyou Xiao, Wei Qi, Tianshu Du, Qiang Sun, Borui Xue, Qinghe Zhao, Pengfei Xie, Zi Ye, Fei Han, Lingli Guo, Yang Jiao, Ranran Zhang, Hong Jia, Xiao Huang, Jianwei Guo, Peng Wang, Huayi Wang, Yuanrui Wang, Wenjing Chen, Haining Wu, Liumin He, Dawei Zhang   +23 more
wiley   +1 more source

Pulmonary toxicity of immune checkpoint inhibitors. [PDF]

Breathe (Sheff)
Garvey S, Nadarajan P.
europepmc   +1 more source

A Radioresistant‐Tumor‐Targeted Nanoparticle for X‐Ray‐Controlled Nitric Oxide Release to Potentiate Radiotherapy

Advanced Science, EarlyView.
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang, Xiaoyan Yin, Ting Wang, Hongfu Zhao, Zhipeng Zhao, Jinbao Wang, Cheng Tao, Xuanchu Ge, Yanze Li, Linlin Liu, Fuxin Xue   +10 more
wiley   +1 more source

Immune checkpoint inhibitors: Unravelling atherosclerotic cardiovascular risk.

1. IntroductionThe development of immune checkpoint inhibitors (ICI) has transformed the landscape of cancer treatment in the past decade with these agents becoming the standard of care in the treatment of many malignancies [1].
Manisty, Charlotte, Mamas, Mamas, Cheng, Richard, Gray, Rhys, Dastidar, Amardeep, Ghosh, Arjun   +5 more
core   +1 more source

Should checkpoint inhibitors be reserved for biomarker-selected pediatric brain tumors? [PDF]

J Neurooncol
Levin-Carrion Y, Bhasin J, Titkov K, Anne S, Sawhney A, Ha CJ, Sharaf I, Jean M, Santana J, Thibault D, Pando A, Novakovic N, Parikh NS, Vojnic M, Sherman JH.   +14 more
europepmc   +1 more source